REGULATORY INTELLIGENCE·Recall
Novo Nordisk's Wegovy (Semaglutide) Injection Faces Nationwide Class II Recall Over Particulate Matter
Novo Nordisk Inc. has initiated a Class II recall (D-0245-2026) for specific lots of Wegovy (semaglutide) Injection due to particulate matter (hair) found in prefilled syringes. This nationwide U.S. recall, impacting a key GLP-1 receptor agonist, necessitates immediate supply chain and quality assurance reviews for procurement and regulatory teams to mitigate disruption and ensure patient safety.
90-Day Activity